LONDON, UK. 12th January 2024 – In a significant stride towards global expansion, Perpetua Life Biotech, a U.S.-based startup specialising in gerontology and longevity medicine, proudly announces the establishment of Perpetua Life Biotech UK Ltd. The newly formed UK entity aims to enhance accessibility for the local market and foster collaborations with UK businesses and retailers.
Founded in 2017 by three biology post-grad students at Boston College, Perpetua Life Biotech embarked on a mission to fill a void in the life extension market. After years of dedicated research and development, the company introduced its flagship product, AEON, in 2021. Dr. Michael Morgan, CEO of Perpetua Life Biotech states: “AEON was created to be an all-in-one longevity focused supplement. Each compound chosen for its stand-alone benefits as well as its synergistic ones paired with the other 10”.
The latest development of the establishment of Perpetua Life Biotech UK Ltd. marks a strategic move to cater directly to the UK market. Despite the US company’s ability to ship worldwide, UK customers faced challenges such as extended delivery times and high customs fees. The new UK presence solves these problems, offering a streamlined and more affordable experience for British customers.
Dr. Michael Morgan, CEO of Perpetua Life Biotech, expressed his enthusiasm about the news, commenting, “We are excited to embark on this new chapter for Perpetua Life Biotech with the establishment of Perpetua Life Biotech UK Ltd. The UK’s reputation as a hub for innovation in the life sciences aligns perfectly with our mission to create transformative biotechnological solutions.
Expect 2024 to continue to deliver encouraging news from Perpetua Life for those interested in Life Extension research and advancements,
For more information, visit https://www.perpetualife.uk